Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial

Starting soon · Phase 2

Conditions studied: Rectal Cancers

In brief

To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer

Key facts

Study ID: NCT07622771
Run by: Sun Yat-sen University
People needed: 84
Starts: 2026-06-01
Expected to finish: 2032-12-31
Last updated by the study team: 2026-06-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients or their family members agree to participate in the study and sign the informed consent form;
Age 18-75 years, male or female;
Locally advanced rectal adenocarcinoma confirmed by histopathology;
Clinical stage cT3-4bN0M0 or cTxN+M0, with or without MRF positive, with or without EMVI positive, expected to R0 resection;
without intestinal obstruction;
ECOG PS 0-1;
expect survival up to 2 years;
White blood cell count > 3.5×109/L；Platelet count ≥ 100×109/L；Hemoglobin ≥ 80 g/L；
ALT ≤ 1.5×ULN, AST ≤ 1.5×ULN ；
Serum creatinine ≤ 100μmol/l,

You may not qualify if…

With inguinal lymph node metastasis or lateral lymph node metastasis (lymph node diameter ≥7 mm, or lymph node morphology and MRI features consistent with typical metastatic lymph nodes);
Arrhythmia requiring antiarrhythmic treatment (except beta-blockers or digoxin), symptomatic coronary artery disease or myocardial ischemia (myocardial infarction within the last 6 months), or congestive heart failure exceeding NYHA Class II;
Severe hypertension poorly controlled with medication;
History of HIV infection, or active hepatitis B (HBV DNA ≥ 2000 IU/mL or 10⁴ copies/mL), or hepatitis C (positive hepatitis C antibody with HCV-RNA above the lower limit of detection of the assay);
Active pulmonary tuberculosis (TB), currently receiving anti-tuberculosis treatment, or having received anti-tuberculosis treatment within 1 year prior to screening;
Other active clinically severe infections (NCI-CTCAE Version 5.0);
Preoperative evidence of distant metastasis outside the pelvis;
Cachexia or organ function decompensation.
History of pelvic or abdominal radiotherapy;
Multiple primary colorectal cancers;
Patients with seizures requiring treatment (e.g., corticosteroids or antiepileptic therapy);
History of other malignancies within 5 years, except cured cervical carcinoma in situ or basal cell carcinoma of the skin;
Drug abuse, or medical, psychological, or social conditions that may interfere with the patient's participation in the study or affect the evaluation of study results;
Active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enterocolitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism);
Receipt of any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment;
Comorbidities requiring long-term treatment with immunosuppressive agents, or requiring systemic or local administration of corticosteroids at immunosuppressive doses (dose >10 mg/day of prednisone or other glucocorticoids with equivalent efficacy);
Known or suspected hypersensitivity to the investigational drug, or to any medication administered in relation to this study;
Any unstable condition that may jeopardize patient safety or compliance;
Pregnant or lactating women, or women of childbearing potential not using adequate contraception;
Refusal to sign the informed consent form.

Where it is running

Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, P. R. China — Guangzhou, Guangdong, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.